EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tumor immune organoids in immunotherapy resistance and drug screening

Minghui Zhang, Lijun Li, Haihong Pu, Yan Wang, Xiaoxin Zhang, Xiaotian Guo, Yanbin Zhao, Qingwei Meng, Mingzhu Yin

Drug Resistance Updates · 2026-03 · 85 · 101360

DOI: 10.1016/j.drup.2026.101360 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026-03. Verfasst von Minghui Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing 404100, China; School of Medicine Chongqi…. Hauptthemen laut MEDLINE: Organoids, Drug Resistance, Neoplasm, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 215 Literaturangaben. Gefördert von: Science Health Joint Medical Scientific Research Project of Chongqing, Chongqing Municipal Education Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor organoids represent a transformative tool in cancer research, as they retain the genetic and phenotypic features of parental tumors and accurately recapitulate their heterogeneity. However, one of the limitations of tumor organoids lies in the lack of immune and stromal cells in the tumor microenvironment (TME). To address this challenge, tumor immune organoids have been developed, which contain complex immune and stromal compartments beyond preserving tumor architecture. Tumor immune organoids show great potential for studying personalized immunotherapy responses and mechanisms of immunotherapy resistance. However, integrating the models into clinical practice remains challenging. In this Review, we outline currently available and rapidly evolving tumor immune organoids that recapitulate the TME and immunotherapy effects. These tumor immune organoids can be established by co-culturing traditional tumor organoids with stromal and immune cells, as well as preserving the TME using microfluidic and air-liquid interface (ALI) culture technologies. Additionally, we delineate the applications of tumor immune organoids for unravelling tumor-intrinsic and -extrinsic immunotherapy resistance mechanisms, predicting immunotherapy efficacy, and facilitating novel drug screening. Finally, we highlight the current challenges of organoid culture technology that need to be addressed for its broader applications, both in basic and translational cancer research. This review provides a theoretical foundation for future research on the application of tumor immune organoids to investigate immunotherapy resistance mechanisms and develop personalized immunotherapies. With continuous advancements, tumor immune organoids are expected to play an increasingly indispensable role in cancer immunotherapy, providing patients with more effective and tailored treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OrganoidsDrug Resistance, NeoplasmImmunotherapyNeoplasmsHumansTumor MicroenvironmentAnimalsDrug Screening Assays, AntitumorPrecision Medicine

Stichwörter der Autor:innen

ImmunotherapyPersonalized treatmentResistanceTumor immune organoidsTumor microenvironment

Autor:innen und Institutionen

  • Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing 404100, China; School of Medicine Chongqing University, Chongqing University, Chongqing 400030, China.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China.
  • Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing 404100, China.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China. Electronic address: zhaoyanbin1978@sina.com.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China. Electronic address: mengqw@hrbmu.edu.cn.
  • School of Medicine Chongqing University, Chongqing University, Chongqing 400030, China; Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC) and Translation…

Förderung

  • Science Health Joint Medical Scientific Research Project of Chongqing
  • Chongqing Municipal Education Commission

Zitieren

APA

Zhang, M., Li, L., Pu, H., Wang, Y., Zhang, X., Guo, X., Zhao, Y., Meng, Q., & Yin, M. (2026). Tumor immune organoids in immunotherapy resistance and drug screening. Drug Resistance Updates, 85, 101360. https://doi.org/10.1016/j.drup.2026.101360

Vancouver

Zhang M, Li L, Pu H, Wang Y, Zhang X, Guo X, et al. Tumor immune organoids in immunotherapy resistance and drug screening. Drug Resistance Updates. 2026;85:101360. doi:10.1016/j.drup.2026.101360

BibTeX
@article{Zhang2026,
  author = {Zhang, Minghui and Li, Lijun and Pu, Haihong and Wang, Yan and Zhang, Xiaoxin and Guo, Xiaotian and Zhao, Yanbin and Meng, Qingwei and Yin, Mingzhu},
  title = {Tumor immune organoids in immunotherapy resistance and drug screening},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {85},
  pages = {101360},
  doi = {10.1016/j.drup.2026.101360}
}
Kostenlos starten →